Divamics Secures Tens of Millions in Series A Funding Led by Yuansheng Venture Capital to Advance AI-Driven Drug Discovery

Investment Circle (ID: pedaily2012) May 6th, according to Arterial Network reports, Divamics Inc., an innovator in drug development based on molecular dynamics (hereinafter referred to as "Divamics")AlreadyCompleted tens of millions of yuan in Series A financing, led by Origin Capital.The funds raised will be used to accelerate the iteration and upgrading of the technology platform and expand the global drug collaboration pipeline.

Divamics, established in 2021, is committed to building an "innovation crucible" for new drug development. By leveraging its proprietary "Molecular Movie" algorithm and early-stage drug discovery decision-making platform, the company efficiently drives new drug innovation and accelerates the discovery of preclinical compounds. Its core technology and platform significantly reduce the preclinical trial-and-error costs of new drug development while enhancing speed and success rates.

Technically, Divamics' self-developed first-generation AI drug design algorithm has officially been granted a U.S. patent. The algorithm uses deep learning to create fingerprint models for each atom type in drugs and target molecules, offering strong interpretability, excelling at uncovering unknown mechanisms at the molecular level, easily discovering new conformations and binding pockets for allosteric drugs, and enabling rational design based on macromolecular flexibility, suitable for drug development across different modalities.

Building on this breakthrough, Divamics has further completed the framework construction of the world’s first kinetic trajectory database. By integrating big data related to drug development, it uncovers the underlying molecular mechanisms behind the pharmacodynamics and pharmacology of different pipelines, efficiently analyzes clinical and patent information, and makes precise decisions in the logical chain of new drug development. It reshapes the innovative chain from molecular discovery to clinical validation, ensuring that drug molecules possess inherent clinical efficacy potential.

In terms of commercialization, Divamics' dual-driven strategy of "deep cultivation in the local market + global expansion" has shown significant results. In the Chinese market, two drug pipelines developed in collaboration with Suzhou BrightGene Bio-Medical Technology and Beijing Anshi Biotechnology respectively entered Phase III clinical trials in the second half of 2024.

In the international market, since the launch of its overseas strategy in the second half of 2024, Divamics has rapidly expanded into overseas markets. Currently, overseas revenue accounts for more than 60% of the company's total income. In particular, a strategic cooperation reached with a leading North American Pharma enterprise last year has led to collaboration on 16 drug pipelines as per the contract terms, and two projects have been successfully delivered so far.

With the deepening of international cooperation, the company has further broken through business boundaries and signed the first "full-package dry and wet lab" order with overseas customers by the end of 2024. By integrating the full-chain capabilities of AI design, dynamic simulation, and experimental validation, Divamics has officially entered a new phase as an integrated solutions provider. To date, Divamics has established extensive cooperation with more than 50 global customers and has participated in over 80 drug discovery pipelines and projects.

Regarding the acquisition of this round of financing, Zheng Zhen, founder of Divamics, stated:Divamics is honored to announce its partnership with YuanSheng Ventures in this round of investment and financing, which is based on the high degree of industrial alignment and synergy between the two parties. Divamics is committed to improving the R&D efficiency of innovative drugs. Our unique technical approach deeply integrates AI with physical simulations, aiming for a more precise understanding of the dynamic interactions and mechanisms between drug molecules and their targets. This allows us to rationally design drugs, predict efficacy and drug-likeness, and overcome traditional bottlenecks in drug discovery. Over the past three years, we have continuously upgraded our core platform through iterations, achieving positive outcomes in collaboration with dozens of global enterprises, validating the technical feasibility and potential, and showcasing a clear value proposition and growth prospects. This round of financing marks further market recognition of the company's technological strength, business model, and team execution capabilities, indicating that the company has entered a more mature phase of value creation. With this financing, we will further expand the types of targets and drug modalities our platform can handle, and establish an operational management system to support global strategic partnerships. All members of Divamics will continue to work tirelessly, driving profound changes in the pharmaceutical industry through continuous innovation and open collaboration, ultimately benefiting patients worldwide.

Dr. Cheng Gang, Partner of YuanSheng Ventures, stated:Based on molecular dynamics models, Divamics combines the latest machine learning and AI technologies to achieve a reasonable balance between simulation accuracy and speed for drug molecule design and optimization. It is applicable to various molecular types, including small molecules, peptides, and antibodies, with the potential to significantly enhance the efficiency of early-stage drug molecule development. Against the backdrop of strong national support for AI-related industries in China, Divamics' work aligns well with this direction, effectively empowering pharmaceutical R&D enterprises both domestically and internationally. YuanSheng Ventures looks forward to supporting Divamics in its continuous innovation and rapid development, becoming a leading company in the AI-assisted pharmaceutical field in China and even globally.